SCHEMBL7038599

SCHEMBL7038599

Cc1cc(O)cc(C(=O)O)c1N

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.68
CYP3A4 P08684 3/20 0.48
ACHE P22303 1/20 0.48
GABRP O00591 1/20 0.44
GABRD O14764 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRB1 P18505 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA5 P31644 1/20 0.44
GABRA3 P34903 1/20 0.44
GABRA2 P47869 1/20 0.44
GABRB2 P47870 1/20 0.44
GABRA4 P48169 1/20 0.44
GABRE P78334 1/20 0.44
GABRA6 Q16445 1/20 0.44
GABRG1 Q8N1C3 1/20 0.44
GABRG3 Q99928 1/20 0.44
GABRQ Q9UN88 1/20 0.44
KMT2A Q03164 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15203462 0.98 KDM4E (0.66) KDM4ECYP3A4ACHEGABRPGABRD
SCHEMBL26963250 0.84 KDM4E (0.50) KDM4ECYP3A4KMT2AMEN1TDP1
SCHEMBL15214028 0.83 KDM4E (0.47) KDM4ECYP3A4ACHEKMT2AMEN1
SCHEMBL17779280 0.83 KDM4E (0.47) KDM4ECYP3A4ACHETDP1ALDH1A1
SCHEMBL5424439 0.81 KDM4E (0.70) KDM4ECYP3A4GABRPGABRDGABRA1
SCHEMBL108376 0.81 KDM4E (1.00) KDM4EGABRPGABRDGABRA1GABRB1
SCHEMBL29502911 0.81 KDM4E (1.00) KDM4EGABRPGABRDGABRA1GABRB1
SCHEMBL1553215 0.81 KDM4E (0.70) KDM4ECYP3A4GABRPGABRDGABRA1
Hydrochloric Acid SCHEMBL5430842 0.79 KDM4E (0.68) KDM4ECYP3A4GABRPGABRDGABRA1
SCHEMBL27462101 0.79 KDM4E (0.68) KDM4EGABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154095-A1 SYNTHESIS METHOD OF AVENANTHRAMIDE C DONG-A UNIVERSITY RESEARCH FOUNDATION FOR INDUSTRY-ACADEMY COOPERATION (KR) 2025-05-15 US claimed
WO-2023140435-A1 METHOD FOR SYNTHESIZING AVENANTHRAMIDES C 동아대학교 산학협력단 2023-07-27 WO claimed
US-20250154095-A1 SYNTHESIS METHOD OF AVENANTHRAMIDE C DONG-A UNIVERSITY RESEARCH FOUNDATION FOR INDUSTRY-ACADEMY COOPERATION (KR) 2025-05-15 US disclosed
WO-2023140435-A1 METHOD FOR SYNTHESIZING AVENANTHRAMIDES C 동아대학교 산학협력단 2023-07-27 WO disclosed
US-20030073862-A1 Compounds BIOVITRUM AB (SE) 2003-04-17 US disclosed
WO-2003004458-A1 NEW COMPOUNDS BIOVITRUM AB (SE) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154095-A1 SYNTHESIS METHOD OF AVENANTHRAMIDE C OAT, MCCC2, OTC KDM4E 1289/4885CYP3A4 1116/4885ACHE 1256/4885
US-20030073862-A1 Compounds PPARG, PPARA, PPARD KDM4E 2125/4885CYP3A4 508/4885ACHE 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.